Baxter infusion pump, dialysis sales rise slowly

Baxter International's ($BAX) sales of infusion pumps and related equipment grew moderately in the 2013 first quarter, reflecting slow growth in the company as a whole.

Sales for the company's fluid systems division--which includes IV therapies and infusion pumps--hit the $740 million mark during the quarter, up about 3% from the $720 million in sales booked during the 2012 first quarter. Baxter's renal division, which includes kidney dialysis equipment and systems, generated $590 million in sales. That's up 1% over Q1 2012, an increase to be sure, but barely an uptick.

Both divisions are part of Baxter's medical products arm, which generated $1.9 billion in sales itself, a 1% dip compared to the same period a year ago. Baxter's overall net sales reached $3.4 billion for the first quarter, a 2% rise from the $3.38 billion generated during the same period in 2012.

That's the good news. But consider that Baxter's $552 million in net income during the quarter represents a 6% drop over the $588 million booked during the 2012 first quarter. What to blame: costs relating to the company's $4 billion acquisition of dialysis company Gambro AB.

Investors offered a pretty muted reaction to Baxter's new numbers. The company's stock traded just under $70 early on April 18, down about $2 from a high reached April 15, but a dip of less than 1% versus the previous day's trading.

- read the release

Suggested Articles

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten offering.

The FDA has announced a series of actions aimed at limiting the use of power morcellators in gynecologic surgeries.

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.